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Background. Although many studies have been published about specific lesions characterizing von Hippel-Lindau(VHL) disease,
none have dealt with the natural history of the whole disease and the consequent disabilities. We aim to define the comprehensive
natural history of VHL disease and to describe the functional disabilities and their impact upon patients’ quality of life, thereby
tailoring the follow-up schedule accordingly.
Methods. We performed a prospective analysis on 128 VHL-affected patients beginning in 1996. For each affected organ, we de-
fined intervals between the first and subsequent VHL-related manifestations and compared them with current VHL surveillance
protocols. We looked for any association of the number of involved organs with age, sex, type of VHL gene mutation, and func-
tional domain mutation. Ultimately, we assessed the organ-specific disabilities caused by VHL disease.
Results. Hemangioblastomas show different patterns of progression depending on their location, whereas both renal cysts and
carcinomas have similar progression rates. Surgery for pheochromocytoma and CNS hemangioblastoma is performed earlier than
for pancreatic or renal cancer. The number of involved organs is associated with age but not with sex, type of VHL gene mutation,
or functional domain mutation. A thorough analysis of functional disabilities showed that age is related to the first-appearing
functional impairment, but it is not predictive of the final number of disabilities.
Conclusions. Our study defines the disease progression and provides a comprehensive view of the syndrome over time. We ana-
lyzed for the first time the functional disability of VHL patients, assessing the progression for each function.
Keywords: disability, follow-up, functional impairment, natural history, VHL.
Von Hippel-Lindau (VHL) disease (OMIM 193300) is a multior-
gan neoplastic syndrome with autosomal-dominant transmis-
sion, complete penetrance, and variable expression that is
caused by mutations in the tumor suppressor VHL gene.1
Affected patients may develop hemangioblastomas in the
CNS, retinal angiomatosis, endolymphatic sac tumors (ELSTs),
clear cell renal carcinomas, pheochromocytomas, renal and
pancreatic cysts, neuroendocrine tumors, epididymal cystade-
nomas, and ovarian cysts (Fig. 1).2,3
The disease has a prevalence of 2–3 per 100 000 and an
estimated incidence between 1 of 36 000 and 1 of 52 000
live births.1,4 All of the mutation carriers usually develop the
clinical features by age 65 years.5 VHL disease was recognized
as a specific syndrome in the early 1900s;6 – 8 however, Latif
identified the VHL gene on the short arm of chromosome
3 (3p25-26) only in 1993.9 The VHL gene encodes for the VHL
protein, which is primarily responsible for hypoxia-inducible
factor 1, alpha (HIF1A) degradation in normoxic conditions.9
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VHL protein has a fundamental role in neoangiogenesis, and
VHL disease is emerging as an extraordinary model of tumor
development and progression. Diagnosis is easier now than it
was in the past, mainly because of genetic testing for VHL
gene mutations. The spectrum of VHL alterations comprises
point mutations in 80% of cases and large deletions in
20%.10,11
Several prospective and retrospective studies have been per-
formed to clarify the natural history of specific lesions charac-
terizing VHL disease.12 – 15 However, no studies about the entire
disease process and comprehensive patient follow-up have
been published to date. Moreover, the disabilities caused by
VHL disease have never been clearly measured or discussed.
In order to better address these issues and to understand
what VHL disease entails for a patient diagnosed with a positive
molecular test, we conducted a prospective analysis of 128 VHL
participants and followed them up for 12 years. In our attempt
to define the natural history and evolution of VHL disease, we
also assessed any genotype-phenotype correlation and surgi-
cal timing for each organ involved with VHL, as they both
might affect the course of the disease. Moreover, we focused
on the participants’ disabilities, which can progressively impair
their quality of life. These data are of utmost importance for
tailoring the follow-up schedule, which is performed every
year at our institution and includes cerebral, spinal, and ab-
dominal nuclear MRI, audiometric testing, wide-field fundus ex-
amination with fluorescein angiography (performed in cases of




A group of 128 participants affected by VHL syndrome was fol-
lowed up by a multispecialist team in Padova, Italy. The
VHL-Padova Network, founded in 1996, is currently the Italian
national reference for patients affected by VHL disease. This
group includes specialists in endocrinology, neurosurgery, urol-
ogy, ophthalmology, otosurgery, general surgery, and molecu-
lar genetics. All VHL-affected patients who were followed up in
Padova since 1996 were included in this study. This group of
128 VHL participants has been monitored for about 12 years,
with an average follow-up of 45 months.
In general, all patients with clinical suspicion of VHL disease
and all relatives of VHL probands were initially referred for
Fig. 1 Diagnostic imaging in von Hippel-Lindau disease. (A) MR T1-weighted axial image with gadolinium showing a cystic cerebellar
hemangioblastoma. (B1) MR T1-weighted sagittal image showing a brainstem hemangioblastoma with syringomyelia (arrows). (B2) MR
T1-weighted sagittal image showing a thoracic spine hemangioblastoma (arrow). (C) CT scan showing a right endolymphatic sac tumor
eroding the petrous bone (circle). (D) MR T2-weighted coronal image showing multiple bilateral renal cysts (arrows) and a left large clear cell
carcinoma (arrowhead) characterized by inhomogeneous signal. (E) MR T2-weighted axial image showing large bilateral adrenal
pheochromocytomas (arrows). (F) MR T2-weighted coronal image showing a polycystic pancreas.
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genetic counseling. After a careful clinical history and physical
examination, DNA analysis of the VHL gene represented the first
step in the diagnostic path.
All participants gave their written consent for all of the
studies, including the molecular analysis and the collection
and management of data. The consent was approved by the
ethical committee of the I.O.V. (Istituto Oncologico Veneto of
Padova), which was notified about the present study.
Molecular Analysis
Genomic DNA was extracted from peripheral blood using the
QIAmp DNA Blood Mini Kit (Qiagen) according to the manufac-
turer’s instructions. Mutation scanning of the VHL gene, for
identification of point- or small-size mutations, was conducted
on the entire coding sequence and intron-exon boundaries by
PCR amplification, denaturing high-performance liquid chroma-
tography, and bidirectional direct sequencing.16 Gross deletion
analysis was performed using Southern blot, quantitative real-
time PCR, and multiple ligation-dependent probe amplification
method (MLPA p016 kit, MRC-Holland).17 Nucleotide numbering
and variant naming followed nomenclature recommendations
of the Human Genome Variation Society.18
Clinical Assessment
Clinical evaluation of individuals found to carry a VHL gene mu-
tation included cerebral, spinal, and abdominal nuclear MRI
(petrous bone CT scan was performed in selected cases when
an ELST tumor was suspected), audiometric testing, wide-field
fundus examination with fluorescein angiography in case of sus-
picious lesions, and measurement of urinary metanephrine and
normetanephrine levels to screen for pheochromocytoma.3,12
All clinical, biochemical, genetic, and imaging data were
included in a database that had been specifically developed
to allow careful and systematic management of VHL patients.
Because the literature does not provide any specific measure
for identifying the complex disabilities due to VHL disease, we
selected some disability-descriptors for each target organ
that are inversely related to the function of the organ itself.
Hence, we prospectively monitored the impairment of each
organ, measuring the disability descriptors over time.
We selected discrete variables because we judged them
to be more suitable for assessing disability than continuous
variables. For example, we initially considered the estimated
glomerular filtration rate for the kidney. However, a participant
with a reduced estimated glomerular filtration rate due to
having undergone resective kidney surgery (and not having to
undergo dialysis), did not have any specific disability affecting
the quality of life. For this reason, we selected the need for dial-
ysis as the descriptor of disability. Similarly, we think the need
for adrenal or pancreatic substitutive therapy represents the
best parameter for assessing the impairment of adrenal and
pancreatic glands; in the same manner, blindness, hypoacusia,
and the presence of neurological sensory or motor impairment
can describe the relevant dysfunction of retina, endolymphatic
sac, and CNS, respectively. Of course, the parameters we select-
ed do not have the same relevance; for example, blindness ob-
viously determines a dramatically worse disability than the
need for pancreatic substitutive therapy. For this reason—
and to illustrate the varying impact of organ involvement—
we decided to distinguish disabilities by specific organs. This de-
cision ruled out the option of using questionnaires to assess
quality of life, which could certainly describe general well-being
but not the impact of specific organ impairment on the quality
of life itself. Karnofsky performance status (KPS) was used to
quantify general well-being and activities of daily life.
Mortality of the group of VHL participants was compared
with the general mortality rate of the Italian population in
the age range of 25 and 65 years (as reported by the Italian
National Institute for Statistics in 2008).
Statistical Analysis
Prevalence ratios, odds ratios, Poisson’s distribution, analysis of
variance, Kaplan-Meier analysis, and Wilcoxon test were used
for statistical analysis. Statistical analysis was performed
using R software (R Core Team, 2015, version 3.2.0).
Results
General Findings
The incidence, age at onset, and time of progression of organ
lesions are shown in Table 1. The average onset intervals ranged
from 25 to 44 years, while the median was 24 to 47 years.
Retinal capillary hemangiomas and epididymal cysts were
the earliest tumors to appear. Cerebellar and brainstem heman-
gioblastomas, pheochromocytomas, ovarian cysts, pancreatic
cysts, and spinal and supratentorial hemangioblastomas were
more delayed, whereas clear cell renal carcinomas, pancreatic
neuroendocrine tumors, and inner-ear lesions were usually
the last.
Natural History of Each Organ Disease
We analyzed the progression of disease in each organ since
the first appearance. We considered “disease progression”
and “evolution” to define the manifestation of a new lesion
and the growth of an already-known lesion, respectively. There-
fore, we were able to perform Kaplan-Meier analysis to show
the loss-of-steadiness for CNS, kidney, and pancreas. The me-
dian survival value was used to define the time to progression
as time is a non-normal distributed variable (Table 1).
We studied the progression of each lesion and compared
both the evolution of the same lesion (hemangioblastoma) in
different locations and the natural history of different lesions
(cysts and solid tumors) in the same organ (results are shown
in Fig. 2).
We observed that the median and the mean ages for
appearance of cerebellar hemangioblastomas were 30 and
27 years, respectively, as reported in the literature.5 They main-
tained a constant pattern of progression, with a median time of
3.5 years between onset and subsequent progressions. The
pattern of progression was different for brainstem hemangio-
blastomas. Although their initial evolution occurs after about
7 years, the subsequent worsening is rather fast (median
time: 1.5 y). The median progression-free survival for spinal
hemangioblastomas progressively halves during their natural
history. Subsequent disease progressions occur at medians
of 5, 2, and 1 years after the onset, respectively. So, each
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progression-free survival time between two progressions lasts
half time compared to the previous progression-free period. It
was not possible to calculate a median evolution time for
supratentorial hemangioblastomas because of the low number
of cases. Therefore, the same tumor may have different growth
patterns depending on its location.
Renal cystic lesions usually appear at the median age of 32
years (mean age: 37 y). They show a first increase in number or
volume after approximately 7 years, but a second progression
occurs after another 1 to 2 years. The median age of appear-
ance for renal clear cell carcinoma is 31 years (mean age:
34 y); the first progression takes place after 7 to 8 years and
the second after another 1 to 2 years. Despite their claimed dif-
ferent biological nature, renal cysts and carcinomas share an
analogous progression pattern and maintain a parallel rhythm
of growth.
Fig. 2. (A) Growth pattern of lesions in the main systems involved in the von Hippel-Lindau disease. (B) Different growth pattern of
hemangioblastomas depending on location. (C) Parallel growth pattern of cysts and renal cell carcinoma.











ercio user on 15 February 2021






























77 (60) 30 27 11.77 49 3.5 28 3.5 14 2 9 3
Brainstem
hemangioblastomas
21 (16) 30 28 10.87 10 7 5 1.5
Spinal
hemangioblastomas
76 (59) 32 29 12.01 26 5 13 2 5 1
Supratentorial
hemangioblastomas
15 (12) 32 30 9.65 2 3
Cystic renal lesions 54 (42) 37 32 12.13 32 7 12 1.5 4 4
Renal cell carcinomas 79 (62) 34 31 11.39 22 8 12 1.5 2 1
Cystic pancreatic lesions 74 (58) 33 30 10.91 36 5 14 3 4 3
Pancreatic endocrine
tumors
26 (20) 34 32 10.29 6 9
Pheochromocytomas 39 (30) 29 29 15.49 5 9
Retinal hemangiomas 74 (58) 29 25 14.20 29 7 4 4
Hypoacusia 14 (11) 42 44 11.5 4 2
Endolymphatic sac
tumors
3 (2) 28 24 8.33 3 2.8
Epididymal
cystadenomas
12 (9) 26 24 10.27 4 6
Ovarian cysts 11 (8) 28 27 8.35
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Pancreatic cysts appear at the median age of 30 years
(mean age: 33 y). They show their first worsening after a medi-
an of 5 years and their second after 3 years. Neuroendocrine
tumors first emerge at the median age of 32 years (mean
age: 34 y), with a progression-free survival of 9 years. It is not
possible to identify another time interval, most likely because
the lesions are removed after their first occurrence or because
their evolution rates are consistent, and our follow up is not
suitable for this purpose.
It was not possible to determine the growth pattern of
pheochromocytomas because they are usually removed as
soon as they are detected. Only 2 of 38 participants affected
by nonsecreting pheochromocytoma were treated with alpha
blockers and thus avoided surgery.
Retinal angiomatosis first develops at the median age of
25 years (mean age: 29 y). Nine participants presented with
unilateral blindness and 3 with bilateral blindness. Multiple
retinal capillary hemangiomas represent a broad group of
lesions that can merge during progression. For this reason,
we could only observe their mean and median ages of ap-
pearance without any precise description of their evolution
through time. In the present series, all 28 participants
who received laser treatment retained normal central vi-
sion. Photocoagulation was not amenable for 3 participants
who underwent surgical procedures and obtained a variable
level of visual function. In one participant, the presence of
bilateral taut and long-standing traction retinal detachment
prevented any medical or surgical approach and led to
blindness.
The onset of ELSTs occurs at a median age of 24 years
(mean age: 28 y). These tumors are likely to progress 2.8
years after their diagnosis, showing either an increase in
volume or a worsening of auditory function. Interestingly,
although we detected sensorineural hearing loss in 14 partici-
pants, imaging was positive for ELST in only 3 cases. As already
reported in the literature, audiometric abnormalities in VHL
patients without any MRI-detectable lesion could be due to
microscopic ELST.24 For this reason, periodic clinical and MRI
surveillance is required.
Ovarian cysts are common findings in the general popula-
tion, while epididymal cystadenoma is a rare benign neoplasm
that is associated with VHL in more than one-third of cases
reported in the literature.13 Epididymal cystadenomas first ap-
pear at a median age of 24 years (mean age: 26 y). Existing
data are not sufficient to describe the development of these
lesions statistically in VHL patients.
Genotype-phenotype Correlation
We analyzed the influence of sex, type of VHL gene mutation,
and functional domain of the mutation (once considered the
effect of age) on the number of organs involved with VHL
lesions. Supplementary material, Table S1 shows the VHL
gene mutations and functional domains of the mutations.
We modeled the number of involved organs through a Poisson
log linear model (Supplementary material, Table S2). However,
the effects of these variables are not significant for predicting
the number of involved organs. As expected, age has a sig-
nificant negative effect (Supplementary material, Table S3,
P , .01).
Surgery Timing
Mean and median ages at first surgery were calculated for the
main organs (Table 2). VHL patients usually undergo several
surgeries during their lifetime. In particular, pheochromocyto-
ma (median age: 25 y) and CNS hemangioblastomas (median
age: 25 y) require surgery earlier than renal cancer (median
age: 36.5 y; P¼ .014 and P¼ .003, respectively). Surgery for
pancreatic neoplasms is usually required later (median age:
31 y) compared with pheochromocytoma (P¼ .043). The Wil-
coxon test was used to compare median ages.
A cumulative incidence of disability was obtained (Fig. 3).
The analysis showed that the major disabilities were those
related to the CNS (34 participants, 26.5%), followed by impair-
ment of visual (21 participants, 16.4%), acoustic (16 partici-
pants, 12.5%), adrenergic (14 participants, 10.9%), pancreatic
(6 participants, 4.6%), and renal (2 participants, 1.5%) func-
tions. We reported one case of vegetative status (0.7%) after
an operation for cerebellar hemangioblastoma. Seven deaths
occurred, due either to postoperative medical complications
(5 cases) or metastases from renal cell cancer (1 case). In
one case, the cause of death was not clear. Including these
patients among the group with CNS disabilities increased the
percentage of impaired participants to 28%. Overall, the aver-
age KPS of the 128 participants was 80% at the end of the
follow-up period.
None of the variables (age, type of VHL mutation, functional
domain mutation) was related to the number and type of
disability. Conversely, only age was found to be significantly as-
sociated with the appearance of the first disability (P , .01),
while sex (P¼ .73), type of mutation (P¼ .34), and functional
domain mutation (P¼ .33) were not predictive.

















Adrenal gland 30 27.3 25 9 59 15 35 14.87
CNS 46 27.8 25 9 51 21 33 10.67
Kidney 24 36.5 31.5 21 62 25 47 12.9
Pancreas 13 34.5 31 24 58 26 38 11.2
Abbreviation: y, years.
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Mortality
Six of our 128 participants died during the follow-up period. In
order to assess the influence of VHL disease on life expectancy,
we compared the mortality rates of the affected participants
between the ages of 25 and 64 years (MR25-64) with those
of the corresponding general population. The MR25-64 of our
VHL population (55.36×103) was significantly higher than the
MR25-64 of the Italian population in the year 2008, which was
1.469×103 (P¼ .0001).
Discussion
General Findings and Natural History of the Disease in
Each Organ
In general, the frequencies of the lesions and the age of onset
are consistent with other published studies;19 – 24 however, the
present study adds data on disease progression. In particular,
cerebellar hemangioblastomas progress constantly with a
3.5-year median evolution time. Conversely, brainstem heman-
gioblastomas first progress after 7 years and subsequently tend
to evolve quickly with a median time of 1.5 years. The median
time for subsequent evolutions of spinal hemangioblastomas
decreases progressively over time. Both renal cysts and carcino-
mas have similar progression rates, with the first progression
after approximately 7 years and following evolutions after
about 1 to 2 years.
Follow up Plan for von Hippel-Lindau Patients
VHL disease has a variable expression, and onset times of the
lesions overlap. As a consequence, designing a proper follow-up
program is challenging. To this purpose, we compared the
median evolution time of lesions with the annual follow-up
schedule adopted at our institution (Fig. 4).
An evolution of a cerebellar hemangioblastoma occurs in 4
years in 50% of the VHL-patient population. This interval is
much longer than the annual deadline established by the cur-
rent follow-up protocol.25 However, if we hypothesized post-
ponement of the first time point follow-up 2 years after the
appearance of the hemangioblastoma, we would delay the
diagnosis of evolution for almost 20% of patients.
A similar analysis was performed for the renal cell carcino-
ma evolution pattern. Also in this case, any attempt to post-
pone the first follow-up to better match the clinical control
schedule with the natural evolution of the lesion resulted
in the unacceptable risk of missing the evolution in a high
percentage of patients. Moreover, a diagnostic delay for
kidney carcinoma is particularly hazardous. In actuality,
surgical treatment is usually planned depending on tumor
size and not on clinical symptoms (as is the case for CNS
hemangioblastomas).
According to our data, an annual check-up ensures correct,
effective, and complete follow up of the disease.
Genotype-phenotype Correlation
The only known genotype-phenotype correlation in VHL disease is
the association of pheochromocytoma (type 2 families) with mis-
sense mutations.26 Conversely, most type 1 families (not affected
by pheochromocytoma) have deletions or premature termination
mutations.27 Recently, Ong et al. pointed out the impact of DNA
mutations on folding of the VHL protein and introduced the con-
cept of functional domain.28 In the attempt to further explore the
correlation between genotype and phenotype in VHL disease, we
investigated the association between some variables (ie, age, sex,
DNA mutation or deletion, and functional domain alteration), the
Fig. 3. Cumulative incidence of disability related to each involved organ.
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number of affected organs, and the order of organ involvement.
The number of involved organs is associated with age. However, it
does not depend on sex, type of VHL gene mutation, or functional
domain mutation. These data confirm the complexity of
VHL disease, which is scarcely defined through a genotype-
phenotype association.
Fig. 4. Kaplan-Meier graphs showing the stability-loss of (A) cerebellar hemangioblastomas and (B) renal cell carcinomas due to an increase in both
volume and number. Green dotted line: first time point used in current follow-up schedule. Red dotted line: delayed first time point for follow up.
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Surgery Timing and Surgical Strategies
Minimally invasive resections (eg, adrenal sparing) are now pre-
ferred, especially for VHL patients who are likely to undergo
recurring surgeries. CNS interventions are usually reserved
only for symptomatic patients and are performed with micro-
surgical techniques.29 Therefore, it is possible to reduce both
intraoperative risks and surgery- related disabilities without
affecting the value of treatment. Early identification of small
retinal capillary hemangiomas is mandatory for providing suc-
cessful laser treatment and preventing retinal exudation and
detachment. In cases in which the diagnosis of retinal lesions
is delayed and laser photocoagulation is not technically feasi-
ble, more aggressive approaches (eg, vitrectomy and retinot-
omy) may eventually be required. If not treated, these retinal
lesions lead to irreversible legal blindness.
Disability
There is a complete lack of information in the scientific litera-
ture about the impact of VHL disease on patients’ everyday
life. Several progressive diseases usually affect patients with
VHL disease, who consequently undergo frequent surgeries.
As a consequence of both disease and surgical interventions,
the function of involved organs might be impaired and worsen
the quality of life for these patients. Our aim was not to provide
only a generic quantification of disability due to the disease it-
self but also to establish the impact of specific organ impair-
ments on patient quality of life. Therefore, we prospectively
focused on the disabilities affecting our study population during
the follow-up period.
Although monocular and binocular blindness and impair-
ment of adrenergic function may occur early in the life of a pa-
tient with VHL disease, the CNS is the most challenging system to
deal with. In almost all cases, disabilities are most likely to occur
during the third and the fourth decades of life, consistent with
the onset of the disease. It is worth noting that dialysis was
very uncommon in our population, probably because early diag-
nosis allowed performance of less-extensive resections.
Seven deaths and one case of vegetative status occurred
during the follow-up period. Medical complications after surgi-
cal or neurosurgical procedures (5) and metastatic progression
of renal cancer (1) were the recognizable causes of death. No-
tably, after an average follow-up period of 45 months, the me-
dian KPS of our participants was 90%, which demonstrated
that VHL-affected patients can still carry on normal activities
with only minor signs or symptoms despite the progression of
disease.
Analysis of variance showed that DNA mutation and func-
tional domain alterations influenced neither the number of dis-
abilities nor their sequence. Moreover, although age is related
to the first-appearing functional impairment, it is not predictive
of the final number of disabilities. This is an important message
to deliver to VHL-affected patients, who can expect a very likely
evolution of their disease with age but not necessarily a wors-
ening of their quality of life.
Mortality Rate
The comparison of the mortality rates between 25 and 64 years
of age of affected patients and general population showed
that, despite the outstanding improvements in diagnostic tech-
niques, strict follow up, and advancements in medical and sur-
gical treatments, VHL disease still significantly increases the
mortality of the affected population.30
Conclusion
VHL is a multifaceted and challenging disease that requires
strict follow-up. Besides the evolution of lesions in each
organ, it is mandatory to consider the complexity of the
whole disease. Patient’s quality of life is affected by the interac-
tion of all phenotypes of the disease. Functional impairment
should be used to summarize the VHL syndrome’s impact on
the participant. Therefore, we suggest considering disability
status as the measure for assessing outcome in this population.
Further studies are necessary to better address the natural
history and functional implications of the most rare VHL lesions
such as ELSTs and epididymal cystadenomas.
Supplementary Material
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